OncoMatch/Clinical Trials/NCT05701241
Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients
Is NCT05701241 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Somatostatin analog for gastroenteropancreatic neuroendocrine tumor.
Treatment: Somatostatin analog — The SAUNA trial is a multi-national, multi-centre, open-label, randomised, controlled, pragmatic clinical trial in patients with advanced, non-functional gastroenteropancreatic (GEP) neuroendocrine tumours (NET) with progressive disease on first-line therapy with somatostatine analogues (SSA). Eligible patients will be divided into two substudies according to the second-line therapy of choice (peptide receptor radionuclide therapy (PRRT) or targeted therapy, at the discretion of the local investigator). Patients within each substudy will be randomised 1:1 between continuation or withdrawal from SSA at the start of second-line systemic therapy. Stratification will occur according to study site and according to the Ki67 value (below 10% (grade 1 and low grade 2) and equal to or above 10% (high grade 2)).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroendocrine Tumor
Pancreatic Cancer
Disease stage
Grade: 12 (who 2019)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: somatostatin analogue — first-line
Documented radiological disease progression on first-line SSA treatment at label dose or higher
Cannot have received: everolimus (everolimus)
Prior treatment with everolimus
Cannot have received: sunitinib (sunitinib)
Prior treatment with sunitinib
Cannot have received: PRRT (Lutetium (177Lu) oxodotreotide)
Prior treatment with PRRT
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05701241 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior everolimus, sunitinib, PRRT disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages